Signs of positive selection of somatic mutations in human cancers detected by EST sequence analysis

BackgroundCarcinogenesis typically involves multiple somatic mutations in caretaker (DNA repair) and gatekeeper (tumor suppressors and oncogenes) genes. Analysis of mutation spectra of the tumor suppressor that is most commonly mutated in human cancers, p53, unexpectedly suggested that somatic evolution of the p53 gene during tumorigenesis is dominated by positive selection for gain of function. This conclusion is supported by accumulating experimental evidence of evolution of new functions of p53 in tumors. These findings prompted a genome-wide analysis of possible positive selection during tumor evolution.MethodsA comprehensive analysis of probable somatic mutations in the sequences of Expressed Sequence Tags (ESTs) from malignant tumors and normal tissues was performed in order to access the prevalence of positive selection in cancer evolution. For each EST, the numbers of synonymous and non-synonymous substitutions were calculated. In order to identify genes with a signature of positive selection in cancers, these numbers were compared to: i) expected numbers and ii) the numbers for the respective genes in the ESTs from normal tissues.ResultsWe identified 112 genes with a signature of positive selection in cancers, i.e., a significantly elevated ratio of non-synonymous to synonymous substitutions, in tumors as compared to 37 such genes in an approximately equal-sized EST collection from normal tissues. A substantial fraction of the tumor-specific positive-selection candidates have experimentally demonstrated or strongly predicted links to cancer.ConclusionThe results of EST analysis should be interpreted with extreme caution given the noise introduced by sequencing errors and undetected polymorphisms. Furthermore, an inherent limitation of EST analysis is that multiple mutations amenable to statistical analysis can be detected only in relatively highly expressed genes. Nevertheless, the present results suggest that positive selection might affect a substantial number of genes during tumorigenic somatic evolution.

[1]  T. Vincent,et al.  An evolutionary model of carcinogenesis. , 2003, Cancer research.

[2]  M. Hsiao,et al.  Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. , 1994, The American journal of pathology.

[3]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[4]  M. Blagosklonny,et al.  p53 from complexity to simplicity: mutant p53 stabilization, gain‐of‐function, and dominant‐negative effect , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[6]  T R Skopek,et al.  Statistical test for the comparison of samples from mutational spectra. , 1987, Journal of molecular biology.

[7]  G. Lozano,et al.  Disrupting TP53 in mouse models of human cancers , 2003, Human mutation.

[8]  Liqing Zhang,et al.  Human SNPs reveal no evidence of frequent positive selection. , 2005, Molecular biology and evolution.

[9]  G. Glazko,et al.  P53 Gain-of-Function: Tumor Biology and Bioinformatics Come Together , 2005, Cell cycle.

[10]  Theodor Boveri.  Zur Frage der Entstehung maligner Tumoren , 1914 .

[11]  S. Haas,et al.  Strengths and weaknesses of EST-based prediction of tissue-specific alternative splicing , 2004, BMC Genomics.

[12]  Illinois.,et al.  Cancer Genetics , 1976, British Journal of Cancer.

[13]  K. Kinzler,et al.  Cancer-susceptibility genes. Gatekeepers and caretakers. , 1997, Nature.

[14]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[15]  P. Vineis.  Cancer as an evolutionary process at the cell level: an epidemiological perspective. , 2003, Carcinogenesis.

[16]  Jarle Breivik,et al.  The evolutionary origin of genetic instability in cancer development. , 2005, Seminars in cancer biology.

[17]  A. Levine,et al.  The p53 pathway: positive and negative feedback loops , 2005, Oncogene.

[18]  G. Glazko,et al.  Mutation hotspots in the p53 gene in tumors of different origin: correlation with evolutionary conservation and signs of positive selection. , 2004, Biochimica et biophysica acta.

[19]  Christopher J. Lee,et al.  Discovery of novel splice forms and functional analysis of cancer-specific alternative splicing in human expressed sequences. , 2003, Nucleic acids research.

[20]  Zhongming Zhao,et al.  Investigating single nucleotide polymorphism (SNP) density in the human genome and its implications for molecular evolution. , 2003, Gene.

[21]  D. Labie,et al.  Molecular Evolution , 1991, Nature.

[22]  Luquan Wang,et al.  Genome wide in silico SNP-tumor association analysis , 2004, BMC Cancer.

[23]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[24]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[25]  G D Schuler,et al.  A workbench for multiple alignment construction and analysis , 1991, Proteins.

[26]  L. Hurst.  The Ka/Ks ratio: diagnosing the form of sequence evolution. , 2002, Trends in genetics : TIG.

[27]  G. Sermonti.  The human genome. , 1988, Rivista di biologia.

[28]  A. Levine,et al.  Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil , 2002, Oncogene.

[29]  I. Hickson,et al.  Caretaker tumour suppressor genes that defend genome integrity. , 2002, Trends in molecular medicine.

[30]  M. Blagosklonny,et al.  Molecular theory of cancer , 2005, Cancer biology & therapy.

[31]  C Lengauer,et al.  Genetic instability and darwinian selection in tumours. , 1999, Trends in cell biology.

[32]  Adams Wt,et al.  Statistical test for the comparison of samples from mutational spectra , 1987 .

[33]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[34]  Jennifer Daub,et al.  Expressed sequence tags: medium-throughput protocols. , 2004, Methods in molecular biology.

[35]  Marcio Luis Acencio,et al.  The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[36]  A. Levine,et al.  Gain of function mutations in p53 , 1993, Nature Genetics.

[37]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[38]  D. Lane,et al.  p53: oncogene or anti-oncogene? , 1990, Genes & development.

[39]  M. Boguski,et al.  dbEST — database for “expressed sequence tags” , 1993, Nature Genetics.